U.S. Diversified Financial Stock News

NYSE:CMRE
NYSE:CMREShipping

Assessing Costamare (CMRE) Valuation After Dividend Reaffirmation And Balance Sheet Progress

What Costamare’s Latest Dividend Move Signals for Investors Costamare (CMRE) recently reaffirmed its income profile by declaring a quarterly dividend of $0.115 per common share, along with scheduled payments on its Series B, C, and D preferred shares. For common shareholders, the $0.115 dividend relates to the quarter ended December 31, 2025 and is payable on February 5, 2026 to investors on record as of January 20, 2026. Preferred investors are set to receive $0.476563 per Series B share,...
NYSE:DDD
NYSE:DDDMachinery

A Look At 3D Systems (DDD) Valuation After Defense Tailwinds And MedTech Milestones

Why 3D Systems Is Back on Investor Radar 3D Systems (DDD) is drawing fresh attention after expanding its U.S. facilities, securing 510(k) clearance for its VSP Orthopedics platform, and advancing defense work supported by the National Defense Authorization Act. See our latest analysis for 3D Systems. These updates have arrived during a volatile stretch, with a 7 day share price return of 25.95% and a 30 day gain of 22.63% following a 90 day decline of 25.08%. At the same time, the 1 year...
NasdaqCM:VFF
NasdaqCM:VFFFood

Is Pomerantz’s Probe Reshaping How Investors View Village Farms’ (VFF) Governance And Growth Ambitions?

Pomerantz LLP recently announced it is investigating potential claims on behalf of investors of Village Farms International, Inc., inviting affected shareholders to contact the firm for more information. This type of investor-focused legal review can intensify scrutiny of Village Farms’ governance and disclosures, adding a new layer of risk perception around the company. We’ll now examine how this investor legal investigation could influence Village Farms International’s cannabis-focused...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story

In recent updates, Celldex Therapeutics reported progression of its antibody pipeline, including global Phase 3 trials for barzolvolimab in chronic urticarias and early-stage data for bispecific antibody CDX-622. A key insight for investors is Celldex’s cash runway reportedly extending through 2027, supporting continued development of these late- and mid-stage programs. Next, we’ll explore how this pipeline momentum, particularly the Phase 3 barzolvolimab program, shapes Celldex...
NYSE:FLO
NYSE:FLOFood

What Do Insider Trades Tell Us About Flowers Foods?

In the last twelve months insiders purchased 12.46k shares for US$207k. On the other hand they divested 562.60k shares, for US$6.8m. In total, Flowers Foods insiders sold more than they bought over the last year (this includes transactions on indirectly owned stock where the insiders do not have full control over the trading decisions).
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

Is It Time To Reassess National Vision Holdings (EYE) After Its 150% One Year Surge

If you are wondering whether National Vision Holdings is still good value after its recent run, looking closely at what the current share price implies can help you set realistic expectations. The stock last closed at US$26.34, with returns of 1.5% over the past week, an 8.6% decline over the past 30 days, 1.5% year to date, a 150.4% gain over the past year, a 35.0% decline over three years, and a 45.8% decline over five years. This combination paints a mixed picture for anyone thinking...